Stock Price Forecast

April 5, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Rubius Therapeutics Inc chart...

About the Company

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.

CEO

Pablo Cagnoni

Exchange

OTC MARKETS

Website

www.rubiustx.com

$M

Total Revenue

269

Employees

$2M

Market Capitalization

-0.43

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RUBY News

Rubius Therapeutics Inc Com Stock (OTC:RUBY) Dividends: History, Yield and Dates

1y ago, source: Benzinga.com

The dividend schedule below includes dividend amounts, payment dates and ex-dividend dates for Rubius Therapeutics Inc Com. Rubius Therapeutics Inc Com issues dividends to shareholders from excess ...

Rubius Therapeutics, Inc. Common Stock (RUBY)

5y ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

Vacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'

7d ago, source:

The 135,000 square-foot former Rubius Therapeutics plant at 100 Commerce Way in February 2023 was acquired by The Davis Companies after Rubius, headquartered in Cambridge, went out of business. Davis ...

Rubius Therapeutics (RUBY) Earnings Dates & Reports

25d ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Rubius Doubles on Progress in Early-Stage Cancer-Drug Trial

3y ago, source: TheStreet.com

Shares of Rubius Therapeutics more than doubled after the biotech reported progress in an early-stage trial of a cancer drug. Rubius Therapeutics (RUBY) more than doubled Monday after the ...

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

1mon ago, source: Business Insider

Life Edit Therapeutics Inc. Before joining ElevateBio, Dr. Pinchasik was a Senior Medical Director at Rubius Therapeutics, Inc., where she supported all clinical-stage pipeline products for the ...

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

2mon ago, source: ADVFN

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and ...

Flagship V VentureLabs Rx Fund, L.P.'s Net Worth

1mon ago, source: Benzinga.com

Who is Flagship V VentureLabs Rx Fund, L.P.? Flagship V VentureLabs Rx Fund, L.P. has an estimated net worth of $211 Million. This is based on reported shares across multiple companies, which ...

Ovid Therapeutics Inc OVID

11h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

Rubius Therapeutics, Inc. (RUBY)

1y ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...